Inbar McCarthy to Cost-Benefit Analysis
This is a "connection" page, showing publications Inbar McCarthy has written about Cost-Benefit Analysis.
Connection Strength
0.252
-
Modi RM, Liu CL, Isaza N, Raber I, Calvachi P, Zimetbaum P, Bellows BK, Kramer DB, Kazi DS. Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure. Circ Cardiovasc Qual Outcomes. 2022 03; 15(3):e008443.
Score: 0.170
-
Isaza N, Calvachi P, Raber I, Liu CL, Bellows BK, Hernandez I, Shen C, Gavin MC, Garan AR, Kazi DS. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Netw Open. 2021 07 01; 4(7):e2114501.
Score: 0.082